Linked Life Data

1849463

Source:http://linkedlifedata.com/resource/pubmed/id/1849463

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1991-5-10
pubmed:abstractText
The rejection of allografts is mediated by cytolytic T cells and antibody-secreting B cells. Selective ablation of these activated cells from peripheral blood lymphocytes may offer a a method of controlling allograft rejection. An immunotoxin was prepared from the monoclonal antibody (mAb) NDA 4, which recognizes a differentiation antigen (NDA 4) common to activated B and T cells. MAb NDA 4 was conjugated to the ribosome-inhibiting protein gelonin via a cleavable disulfide bond provided by a crosslinking reagent. The purified immunotoxin was evaluated for in vitro cytotoxicity on NDA 4 positive T and B cell lines. Conjugation of mAb NDA 4 to gelonin increased the in vitro cytotoxicity by a concentration factor of 1000, compared to gelonin alone. The specificity and saturability of mAb NDA 4 binding, as well as the number of antigenic sites per cell on resting versus activated T lymphocytes, were also evaluated. Resting T cells expressed 400-800 sites per cell. PHA-activated T cells and the MLA T cell leukemia expressed 10,000 to 80,000 sites per cell. Peripheral blood mononuclear cells obtained from allografted baboons in quiescence or undergoing rejection were compared for NDA 4 expression by flow cytometry. Lymphocytes obtained from baboons rejecting a heart allograft expressed NDA 4, whereas transplant recipients in quiescence showed no detectable NDA 4. These results suggest that mAb NDA 4-derived immunotoxins may be valuable for the selective depletion of activated lymphocytes while sparing the resting population.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0008-8749
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
134
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
85-95
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:1849463-Animals, pubmed-meshheading:1849463-Antibodies, Monoclonal, pubmed-meshheading:1849463-Antibody Affinity, pubmed-meshheading:1849463-Antibody Specificity, pubmed-meshheading:1849463-Antigens, Differentiation, pubmed-meshheading:1849463-B-Lymphocytes, pubmed-meshheading:1849463-Blotting, Western, pubmed-meshheading:1849463-Cell Line, pubmed-meshheading:1849463-Cell Transformation, Viral, pubmed-meshheading:1849463-Cytotoxicity, Immunologic, pubmed-meshheading:1849463-Graft Rejection, pubmed-meshheading:1849463-Heart Transplantation, pubmed-meshheading:1849463-Herpesvirus 4, Human, pubmed-meshheading:1849463-Hylobates, pubmed-meshheading:1849463-Immunotoxins, pubmed-meshheading:1849463-Lymphocyte Activation, pubmed-meshheading:1849463-Plant Proteins, pubmed-meshheading:1849463-Ribosome Inactivating Proteins, Type 1, pubmed-meshheading:1849463-Species Specificity, pubmed-meshheading:1849463-T-Lymphocytes
pubmed:year
1991
pubmed:articleTitle
In vitro studies of the effect of MAb NDA 4 linked to toxin on the proliferation of a human EBV-transformed lymphoblastoid B cell line and of gibbon MLA leukemia cell line.
pubmed:affiliation
College of Physicians & Surgeons of Columbia University, Department of Pathology, New York, NY 10032.
pubmed:publicationType
Journal Article, Comparative Study, In Vitro, Research Support, U.S. Gov't, P.H.S.